Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Derivados de pirrolidina como inibidores de fosfodiesterase especìfico amp cìclico

Abstract

"DERIVADOS DE PIRROLIDINA COMO INIBIDORES DE FOSFODIESTERASE ESPECìFICO AMP CìCLICO". São descobertos novos compostos de pirrolidina contendo a fórmula estrutural (II) que são inibidores potentes e específicos da PDE4, assim como métodos para fabricação dos mesmos. Também são descobertos os usos desses compostos no tratamento de doenças inflamatórias e outras desordens envolvendo elevados níveis de citoquinas, bem como desordens do sistema nervoso central (SNC).

Classifications

C07D207/08 Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
View 46 more classifications

Landscapes

Health & Medical Sciences Chemical & Material Sciences
Show more

BR0016693A

Brazil

Find Prior Art Similar
Other languages
English
Inventor
Timothy J Martins
Kerry W Fowler
Joshua Odingo
Laurence E Burgess
Edward A Kesicki
Amy Oliver
John J Gaudino
Zachary S Jones
Bradley J Newhouse
Stephen Schlachter
Worldwide applications
1999 US 2000 US CA DE AU PL UA KR IL CZ GE RS EP MX EA EE JP AT CN BR TR HU WO SK 2001 US 2002 US IS HR NO BG ZA 2003 HK 2004 US 2005 US
Application BR0016693-6A events
2000-11-28
Application filed by Icos Corp
2003-03-11
Publication of BR0016693A
2015-09-01
Publication of BRPI0016693B1
Info
Patent citations (10)
Cited by (53)
Legal events
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (10)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
JPS5821622B2 * 1973-02-28 1983-05-02 ウェルファイド株式会社 ピロリジンメタノ−ル ノ セイゾウホウ
JPS50108258A * 1974-02-08 1975-08-26
US5665754A * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
CA2143143A1 * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
JPH07300455A * 1994-03-08 1995-11-14 Mitsubishi Chem Corp ３−フェニルピロリジン誘導体
US5998428A 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US5856103A * 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
DE19601938A1 * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
CN1254335A * 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
US6258833B1 * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
* Cited by examiner, † Cited by third party

Cited By (53)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
US6455571B1 * 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
US6258833B1 * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20010049368A1 * 2000-02-29 2001-12-06 Reines Scott A. Method for treating or preventing depression
WO2002002500A1 * 2000-07-03 2002-01-10 Speedel Pharma Ag Preparation of (r)-2-alkyl-3-phenylpropionic acids
US6953774B2 * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2002047540A2 * 2000-12-15 2002-06-20 The General Hospital Corporation Methods for inhibiting fibrosis
US20040014099A1 * 2001-03-19 2004-01-22 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
US6479493B1 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
KR20090080573A * 2001-10-16 2009-07-24 메모리 파마슈티칼스 코포레이션 신경계 증후군의 치료를 위한 ｐｄｅ-4 억제제로서의 4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체
ES2293965T3 * 2001-12-14 2008-04-01 Laboratoires Serono Sa Metodo de inducir la ovulacion utilizando un modulador no polipeptidico de los niveles de camp.
MY140561A 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE10228132A1 * 2002-06-24 2004-01-22 Arzneimittelwerk Dresden Gmbh Amide cyclischer Aminosäuren als PDE 4 Inhibitoren
ME00524B 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
WO2004094375A2 * 2003-04-16 2004-11-04 Memory Pharmaceuticals Corporation 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
CA2522687A1 * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
EP1635834A4 * 2003-06-25 2009-12-02 Smithkline Beecham Corp NEW COMPOUNDS
AU2004277932B2 * 2003-09-30 2009-07-16 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
US20050201989A1 * 2004-02-19 2005-09-15 St. Camillus Medical, Inc. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha
ES2317223T3 * 2004-04-08 2009-04-16 Wyeth Derivados de tioamida como moduladores del receptor de progesterona.
US7432266B2 * 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7585882B2 * 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2601250C * 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
EP2258357A3 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR20080065704A 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US20100216734A1 * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100009983A1 * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2663347A1 * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CL2007002958A1 * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
KR20100049644A 2007-08-07 2010-05-12 다케다 야쿠힌 고교 가부시키가이샤 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
AU2008335135A1 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
WO2010099217A1 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102603623A * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
WO2013106547A1 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JO3264B1 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
ES2733552T3 * 2014-01-24 2019-11-29 Celgene Corp Procedimientos para el tratamiento de la obesidad mediante apremilast
AU2015268505C1 * 2014-05-29 2018-04-05 Mitsubishi Tanabe Pharma Corporation Novel pyrrolidine compound and application as melanocortin receptor agonist
WO2016033776A1 * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
AR101696A1 * 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
WO2017072796A1 2015-10-30 2017-05-04 Council Of Scientific & Industrial Research 2-pyridone based compounds useful as potential phosphodiesterase3a (pde3a)inhibitors and a process for the preparation thereof
JP6392297B2 * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物
ES2967094T3 2017-09-29 2024-04-26 Mitsubishi Tanabe Pharma Corp Compuesto de pirrolidina ópticamente activo y procedimiento de producción del mismo
JP7227380B2 * 2018-12-18 2023-02-21 武漢人福創新薬物研発中心有限公司 フェニルピロリジン化合物及びその用途
CN112409333B * 2019-08-23 2024-06-14 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物
TW202146385A * 2020-04-29 2021-12-16 大陸商廣東東陽光藥業有限公司 取代的吡咯烷類化合物及其在藥物中的應用
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
BR0016693A 2003-03-11 Derivados de pirrolidina como inibidores de fosfodiesterase especìfico amp cìclico
DK1242415T3 2004-06-01 3-thiazol-4-yl-pyrolidinderivater som AMP-specifikke phosphodiesteraseinhibitorer
EA200000171A1 2000-10-30 2-аминопиридины, содержащие в качестве заместителей конденсированные кольца, применяемые в качестве ингибиторов nos (no синтазы)
BR0308937A 2005-01-04 Compostos imidazo fundidos
NO20065948L 2007-01-23 Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
BR0016687A 2003-02-25 Pirrolidinas que inibem a pde especìfica do ampc
HUP0001539A2 2000-11-28 2-(1-Imino-etil-amino)-etil-homocisztein, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmények
DOP2005000022A 2005-08-30 "derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina"
BR0008958A 2001-11-27 Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
DK1017692T3 2004-07-12 4-Heteroaryl-tetrahydroquinoliner og deres anvendelse som inhibitorer af cholesterolester-transferproteiner
BR0112786A 2003-07-01 Inibidores de inflamação não-esteroidais
UY24799A1 2001-08-27 Derivados de 6-fenilpiridil-2-amina
DK1311256T3 2005-11-28 Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
DK1339406T3 2004-09-27 Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
EA199900632A1 2000-02-28 2-амино-6-(2-замещенные-4-фенокси)-замещенные-пиридины
ES2187738T3 2003-06-16 Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
ATE367380T1 2007-08-15 Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE247645T1 2003-09-15 Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
UY26426A1 2001-05-31 Nuevos compuestos
DE60018470D1 2005-04-07 Cyclische amp spezifische phosphodiesterase inhibitoren
BR0109589A 2003-02-04 Derivados de pirano[2,3-c]imidazo[-1,2-a]piridina para o tratamento de distúrbios gastrointestinais
TR200103398T2 2002-03-21 íkameli fenilsikloheksankarboksamitler ve bunlarìn adenozin alìnìmìnìn inhibit”rleri olarak kullanìmì
EA199800192A1 1999-06-24 Применение ингибиторов фосфодиестеразы (pde) в производстве лекарственных препаратов для лечения заболеваний мочевого пузыря

Priority And Related Applications

Applications Claiming Priority (2)

Application Filing date Title
US09/471,846 1999-12-23 Cyclic AMP-specific phosphodiesterase inhibitors
PCT/US2000/032401 2000-11-28 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors

Legal Events

Date Code Title Description
2009-12-29 B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2011-05-24 B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2012-12-04 B09A Decision: intention to grant [chapter 9.1 patent gazette]
2013-09-17 B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
2015-09-01 B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS.
2017-09-26 B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
2018-01-16 B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
cardiac stimulant phosphodiesterase inhibitors title,abstract 2 0.000
phosphodiesterase inhibitor title,abstract 2 0.000
pyrrolidines title,abstract 2 0.000
Cyclic adenosine monophosphate title 1 0.000
cyclic amp title 1 0.000
central nervous system abstract 2 0.000
diseases, disorders, signs and symptoms abstract 2 0.000
Cytokines abstract 1 0.000
Cytokines abstract 1 0.000
Dictyostelium discoideum Pde4 gene abstract 1 0.000
Plasmodium falciparum (isolate 3D7) PDEdelta gene abstract 1 0.000
Pyrrolidine abstract 1 0.000
compounds abstract 1 0.000
inflammatory disease abstract 1 0.000
inhibitor abstract 1 0.000
manufacturing process abstract 1 0.000
method abstract 1 0.000
potentiating effect abstract 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services